BioSpace News Archive

Phase 3 studies for diabetic macular edema and retinal vein occlusion enrolling well and on track for topline results also in 2022

Guardant Health, Inc. announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Vaccine candidate now expected to remain stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days, up from previous estimate of 7 days

Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced the expansion of Myriad myChoice® tumor testing in several European markets and China.

Commercialization preparedness activities continuing ahead of December 30 PDUFA date for FUROSCIX® (furosemide injection) for subcutaneous administration

Skin Reaction or “Take,” a Validated Biomarker of Functional T cell Immunity, Elicited in All Eight TNX-1800 Vaccinated Animals

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences: Jefferies London Virtual Healthcare Conference Tuesday, November 17, 2020 11:25 am Eastern Time Piper Sandler 32 nd Annual Virtual Healthcare Conference Monday, November

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the U.S. Food and Drug Administration has accepted and granted Priority Review designation for the New Drug Application for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.

Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced it will host a virtual R&D day on Tuesday, November 24, to review the Company’s key pipeline programs including etigilimab for solid tumors and alvelestat for alpha-1 antitrypsin deficiency and COVID-19 respiratory disease.

Continued progress in OVAL Phase 3 potential-registration study in patients with platinum-resistant ovarian cancer; high response rates (RR) of over 50% in the total evaluable patient population with approximately 200 patients enrolled to date